Palatin's Latest Quarter: Vyleesi Surges, Key Drug Trials Advance, and a Glimpse into the Future
Palatin Technologies Secures Major Milestone Payment in Groundbreaking Retinal Disease Collaboration with Boehringer Ingelheim